BCAL Diagnostics Limited (ASX: BDX)
Health Care · Biotechnology · AU
AU$0.08
-12.22% today · -2.5% 1Y
BCAL Diagnostics Limited (ASX: BDX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $20.15M and employs 6 people.
Over the last twelve months the share price has lost 2.5%, trading between 0.05 and 0.16.
Tweenvest scores BCAL Diagnostics Limited across four factors: quality 25/100, value 47/100, growth 100/100. Its strongest factor is growth.
BDX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.15M
- Revenue (TTM)
- $1.63M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.74
- 52-week high
- AU$0.16
- 52-week low
- AU$0.05
- Avg volume (3M)
- —
- Shares outstanding
- 368.68M
- Employees
- 6
- Next earnings
- —
About BCAL Diagnostics Limited
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
- ISIN
- AU0000160921
- Founded
- 2010
- Listed since
- Jul 21, 2021
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| APTOCROM Inc.KOSDAQ: A109960 | $20.66M | ₩1,821.00 | -5.50% |
| ProBiotix Health PlcOFEX: PBX | $20.57M | £0.10 | +2.63% |
| Taiwan Advance Bio-Pharmaceutical Inc.TPEX: 4186 | $20.25M | NT$7.30 | -3.31% |
| FF EAI Robotics Ecosystem Inc.NasdaqCM: FFR | $20.23M | $1.00 | -7.41% |
| MDxHealth SANasdaqCM: MDXH | $19.71M | $0.21 | -64.97% |
| Modalis Therapeutics CorporationTSE: 4883 | $19.56M | ¥29.00 | -3.33% |
| Elicera Therapeutics AB (publ)OM: ELIC | $19.51M | Skr2.90 | +5.08% |
| Nexsen LimitedASX: NXN | $19.50M | AU$0.14 | +7.69% |
Figures last refreshed Oct 18, 2026.